Lupin Receives FDA Approval for Apixaban Oral Suspension
Mumbai, India, and Naples, Florida, U.S., September 28, 2026 Lupin Limited has reached an important U.S. regulatory milestone after...
505(b)(2)
Advertisement
Ocular Therapeutix Advances AXPAXLI Toward Wet AMD NDA
BEDFORD, Mass. — September 15, 2026 Ocular Therapeutix, Inc. announced the successful completion of its Pre-New Drug Application (Pre-NDA)...
Curium Gains FDA Approval for BEXLUTRY in GEP-NETs
BOSTON, Mass. — September 14, 2026 Curium™ announced that the U.S. Food and Drug Administration (FDA) has approved its...
Teitur Trophics Advances TT-P34 Toward Phase II in Parkinson’s
AARHUS, Denmark — September 10, 2026 Teitur Trophics announced successful results from the Phase I clinical trial of TT-P34,...
EPIK Biosciences Expands Ketamine and DXM Drug Portfolio
AUSTIN, Texas — September 10, 2026 EPIK Biosciences announced continued progress in developing proprietary synergistic combination medicines targeting mental...
Advertisements
Silo Pharma Advances Canadian Patent for PTSD Therapy
SARASOTA, Fla., August 18, 2026 Silo Pharma, Inc. announced that the Canadian Intellectual Property Office (CIPO) has issued a...
Cycle Pharmaceuticals Partners With Forma Life Sciences for CAVHANZA Supply
IRVINE, Calif., August 12, 2026 Cycle Pharmaceuticals announced a commercial manufacturing agreement with Forma Life Sciences to establish a...
Entera Bio Advances EB613 Toward Phase 3 Development Following FDA Alignment
TEL AVIV, August 7, 2026 Entera Bio reported its second quarter 2026 financial results and business updates, highlighting regulatory...
Advertisement
